Advances in Liposomal Nanocarriers for Cancer Drug Delivery: Mechanisms, Targeting Strategies, and Clinical Perspectives

Imagine a world where medicine could travel through the body like a specialized courier, carrying a fragile package directly to a specific destination while leaving everything else untouched. This is the promise of drug delivery, a field dedicated to moving therapeutic substances into patients in a way that maximizes healing and minimizes harm. For decades, scientists have struggled with the fact that many powerful drugs, especially those used to fight cancer, are like blunt instruments. They circulate freely in the bloodstream, attacking healthy cells alongside diseased ones, which leads to severe side effects and limits how much medicine a patient can safely receive. Furthermore, many drugs break down too quickly in the body or fail to dissolve properly, meaning they never reach the cells that need them. To solve this, researchers have turned to nanotechnology, a branch of science that designs materials at a scale so small it is measured in billionths of a meter. At this size, materials behave differently, offering new ways to protect medicines and guide them precisely where they are needed.

One of the most promising tools emerging from this field is the liposome. You can think of a liposome as a microscopic bubble made from the same fatty materials that make up the outer walls of our own cells. Because these bubbles are built from natural components, the body recognizes them as friendly, allowing them to circulate safely without triggering a strong immune attack. Inside this protective shell, scientists can trap medicines. If a drug dissolves in water, it sits in the liquid center of the bubble; if it is oily, it gets tucked into the fatty walls of the bubble itself. This simple structure allows researchers to shield delicate drugs from the harsh environment of the body, keep them stable for longer periods, and carry both water-loving and oil-loving substances at the same time.

In a comprehensive review published by researchers at Babasaheb Bhimrao Ambedkar University, the focus is on how these liposomal carriers have evolved from simple containers into sophisticated delivery systems for cancer treatment. The authors, Chandraprakash Gond and his colleagues, examine the entire lifecycle of these tiny vessels, from how they are built to how they interact with cancer cells. They explain that modern liposomes are no longer just passive carriers. Through advanced engineering, scientists can now adjust their size, charge, and surface properties to make them smarter. For instance, by adding a specific coating, researchers can extend the time a liposome stays in the bloodstream, giving it more opportunity to find a tumor. They can also attach specific markers to the surface that act like a key, unlocking only when the liposome encounters a cancer cell, ensuring the drug is released exactly where it is needed.

The paper details the various methods scientists use to manufacture these structures. Some techniques involve mixing lipids with water under high pressure to force them into tiny, uniform spheres, while others use solvents that evaporate to leave behind a solid drug core wrapped in a lipid shell. The researchers highlight that the choice of method matters greatly, as it determines how much medicine the liposome can hold and how steadily it releases that medicine. They also discuss the shift toward "hybrid" systems, which combine the best features of lipid bubbles with synthetic polymers. These hybrid carriers aim to solve the weaknesses of using lipids or polymers alone, offering better stability and the ability to carry larger doses of medication.

A significant portion of the review is dedicated to how these systems are currently being used in the clinic and how they might be used in the future. The authors point out that liposomal drugs have already been approved for treating certain types of leukemia and breast cancer, proving that the concept works in real patients. These approved treatments have shown that liposomes can reduce the toxic side effects of chemotherapy while maintaining, or even improving, the drug's ability to kill cancer cells. The review also explores how these carriers are being adapted for other medical challenges, such as delivering genes to repair faulty DNA, treating eye diseases by bypassing barriers that usually block eye drops, and even helping drugs cross the blood-brain barrier to treat conditions like Alzheimer's and Parkinson's.

Despite these successes, the authors are careful to note that the field is not without its hurdles. Scaling up the production of these complex nanoparticles from a small laboratory batch to a large factory run is difficult and expensive. There are also concerns about how the body reacts to the synthetic materials used in some of these carriers, and the variability of tumors in different patients means that a delivery system that works for one person might not work for another. The paper concludes that while liposomal nanocarriers represent a massive leap forward in how we treat disease, the journey is ongoing. The future lies in refining these systems to be even more precise, affordable, and tailored to the unique biology of each patient, moving medicine closer to a future where treatments are not just effective, but also gentle and highly specific.